Navigation Links
Rik Deitsch, CEO of Nutra Pharma Creates Personal Wall on WallSt.net's Financial Social Community, my.wallst.net
Date:4/18/2008

NEW YORK, April 18 /PRNewswire-FirstCall/ -- Rik J. Deitsch, Chairman and Chief Executive Officer of Nutra Pharma Corporation (OTC Bulletin Board: NPHC) (http://www.NutraPharma.com) will be updating the investment community through his personal profile on MyWallst.net available at http://www.wallst.net. The dynamic profile will include exclusive interviews with Rik J. Deitsch, company blogs on which investors can comment, his personal stock watchlist, photos of company products and links to recent press.

Visit Rik J. Deitsch's profile on My.wallst.net at http://my.wallst.net/profile.php?ID=20002.

Stay updated about Nutra Pharma Corporation, ask Rik a question or post a comment on his personal page. Join Nutra Pharma's message board to discuss company activity with other interested parties, "invest" in OTCBB: NPHC through the Rookie Challenge and join his financial social network today.

About WallSt.net:

http://www.wallst.net is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. (http://www.financialmediagroupinc.com). The Web site is a leading provider of timely business news, executive interviews, multimedia content, and research tools. Financial Media Group, Inc. also owns http://my.wallst.net, a financial social network for investors, and Financial Filings Corp. (http://www.financialfilings.com), a provider of compliance solutions to publicly traded companies. We have received ten thousand dollars from Nutra Pharma Corporation for media and advertising services. In addition to WallSt.net, WallStreet Direct, Inc. owns and operates WallStRadio (http://www.wallstradio.com), a business and finance podcast Web site.

About Nutra Pharma:

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ('MS'). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

Contact: Nutra Pharma Corporation

877-895-5647

IR@NutraPharma.com


'/>"/>
SOURCE Nutra Pharma Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Demand for NutraCea Rice Bran Oil Prompts Major Expansion of Irgovel Plant Ahead of Schedule
2. NutraCea-Sponsored Study Demonstrates Benefits of Replacing Wheat Flour with Stabilized Rice Bran (SRB) in Battered and Fried Product Applications
3. NutraCea Appoints New Chief Financial Officer
4. New World Record Holder in Powerlifting Credits NutraCeas Unique Rice-Bran-derived Product as his Secret Weapon
5. Nellson Nutraceutical Names New Directors and Interim Chief Executive Officer
6. NutraCea to Purchase Largest Rice Bran Oil Processing Facility in South America
7. Nutraceutical Reports Fiscal 2008 Q1 Results
8. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
9. NutraCea Files Universal Shelf Registration Statement
10. NutraCea Provides Update on Domestic Operations
11. Synutra International, Inc. Amends August 2005 Current Report on Form 8-K and Annual Report on Form 10-K for the Fiscal Year Ended March 31, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... ... “The Inn at the Mill”: a story of love and redemption, hope and uncertainty ... and content. , “The Inn at the Mill” is the creation of published author, ... and is now living in Berks County on Crow Hill. The inn, the ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... programs and resources at seafoodnutrition.org/programs and seafoodnutrition.org/resources to assist in teaching communities ... These resources have been developed for use by nutrition educators and influencers ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Some Infallible Characteristics of Christ”: a ... Characteristics of Christ” is the creation of published author, Rev. Dr. Robert W. Thomas, ... thirteen years, a preacher for over nineteen, a pastor for over fifteen years. He ...
(Date:1/22/2017)... ... January 22, 2017 , ... Phytocéane invites clients to take an ... of the world with ZANZIBAR MILKY CREAM. Inspired by the beauty of Zanzibar, a ... Coconut Oil and moisturizing vegetal coral to create this gentle, velvety body cream to ...
(Date:1/22/2017)... ... 22, 2017 , ... "Photo Cloud allows FCPX users to add favorited photos ... complete ease," said Christina Austin - CEO of Pixel Film Studios. , To ... timeline. Presets include scenes with one, three, four or five focus points. There ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... 2017 Stock-Callers.com today evaluates the following ... ), Novo Nordisk A/S (NYSE: NVO ), Sucampo ... Holdings Inc. (NASDAQ: PTX ). These stocks belong ... th , 2017, finishing near its session lows. As per ... 0.7%, while shares of health care companies in the S&P ...
(Date:1/20/2017)... January 20, 2017 Avillion LLP, a co-developer ... Mark Weinberg , MD MBA as Chief Medical Officer. Dr ... USA . ... Dr Weinberg has spent more than 17 years as a ... companies to micro-cap biotech. Over the course of his career, he ...
(Date:1/19/2017)... Jan. 19, 2017 The U.S. Food and Drug ... Idiopathic Constipation (CIC) in adult patients. "No ... disorders," said Julie Beitz , M.D., director of the ... Drug Evaluation and Research. "With the availability of new therapies, ... for their condition." ...
Breaking Medicine Technology: